3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
9
Pancreatic Neoplasms
7
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Colonic Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Osteosarcoma
2
Myelodysplastic Syndromes
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Glioma
2
Fibrolamellar hepatocellular carcinoma
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urologic Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
pembrolizumab
26
Nivolumab
18
enfortumab vedotin
7
avelumab
6
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
fludarabine
4
cabozantinib
4
Gemcitabine
4
Cyclophosphamide
4
Carboplatin
4
Specimen Handling
3
Interleukin-2
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
aldesleukin
2
Platinum
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
vinflunine
1
veliparib
1
valrubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Transitional Cell
×
poly ICLC
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled